Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 470 of 6351
-
Engineered immune cells from cord blood take on tough lymphoma
Disease control Recruiting nowThis study aims to evaluate the safety and efficacy of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 (TRBC1/2 CAR-NK cells) in patients with refractory or relapsed peripheral T-cell lymphoma (PTCL).
Phase 1 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for hepatitis d: experimental drug enters final testing phase
Disease control Not yet recruitingThis study adopts a multicenter, randomized, double-blind, placebo-parallel controlled design to evaluate the efficacy and safety of L47 in the treatment of chronic hepatitis D. A total of 150 subjects are planned to be enrolled. After passing the screening, they will be randoml…
Phase 3 • Sponsor: Shanghai HEP Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for aggressive lymphoma: drug cocktail aims to control High-Risk MCL
Disease control Recruiting nowto learn if giving glofitamab after treatment with BTKi-rituximab can help to control high-risk MCL.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New vaccine aims to shield african infants from two deadly infections
Vaccine Recruiting nowThe purpose of this study is to evaluate the safety, reactogenicity, and immune response induced by the GlaxoSmithKline Biologicals SA (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid conjugate (iNTS-TCV) vaccine in infants with the first…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jun 27, 2026 12:10 UTC
-
New hope for lung cancer patients who Can't take chemo
Disease control Recruiting nowThe purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent RT and maintenance osimertinib in chemotherapy ineligible or refusal adult patients with Stage III, unresectable NSCLC with common EGFR mutations (exon 19 dele…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Promising new combo aims to extend life in rare, Tough-to-Treat cancer
Disease control Not yet recruitingBackground Neuroendocrine carcinomas (NECs) of gastro-entero-pancreatic (GEP) or unknown (UK) origin are rare and highly aggressive diseases. The recommended first-line (L1) treatment is platinum-etoposide combination therapy, which has a progression-free survival (PFS) of only 4…
Phase 2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Morning vs afternoon: can timing boost kidney cancer treatment?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if the timing of treatments plays a role in how effective the standard-of-care drugs nivolumab/ipilimumab (ICI/ICI) works to treat adults with advanced kidney cancer. The trial will also learn if time-of-day reduces ICI/ICI side-effects…
Phase 3 • Sponsor: Guliz Ozgun • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Spinal injury breakthrough: brain zaps may restore grip
Symptom relief Recruiting nowThe goal of this study is to restore the activities of late descending signals with a noninvasive stimulation approach in combination with hand motor training to improve hand function in persons with cervical SCI. The main question it aims to answer is if the inputs to late desce…
Sponsor: State University of New York at Buffalo • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
New hope for tough esophageal cancer: drug combo targets gene mutations
Disease control Not yet recruitingA Randomized, Open-Label, Parallel-Controlled, Multicenter Phase III Clinical Trial to Evaluate the Safety and Efficacy of Anlotinib Hydrochloride Combined with Benmelstobart versus Toripalimab Combined with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Ce…
Phase 3 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New blood test could personalize AML treatment
Diagnosis Not yet recruitingThis is a therapeutic intervention trial evaluating the clinical utility of a novel blood-based epigenetic biomarker-genome-wide 5-hydroxymethylcytosine (5hmC) in cell-free DNA (cfDNA)-for assessing measurable residual disease (MRD) in patients with newly diagnosed acute myeloid …
Phase 2 • Sponsor: The Methodist Hospital Research Institute • Aim: Diagnosis
Last updated Jun 27, 2026 09:11 UTC
-
New drug combo aims to tame rare artery disease
Disease control Not yet recruitingThis is a prospective, open-label, controlled, multiple centers, randonmized clinical trial. It compares the clinical efficacy and safety of vunakizumab ivarmacitinib and glucocorticoids in the treatment of active Takayasu's arteritis.
Phase 4 • Sponsor: Chinese SLE Treatment And Research Group • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Could freezing breast cancer replace the knife? major trial launches
Disease control Not yet recruitingThe goal of this randomised controlled trial is to compare ipsilateral breast cancer recurrence rates in patients with early-stage breast cancer between patients treated with breast conserving surgery and patient treated with percutaneous cryo-ablation.
Phase 3 • Sponsor: Franciscus Gasthuis & Vlietland (Hospital) • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for Drug-Resistant leukemia: phase 3 trial launches
Disease control Not yet recruitingA Phase III study evaluating the safety and efficacy of TGRX-678 in CML-CP patients resistant from or intolerant to at least 3 TKIs
Phase 3 • Sponsor: Shenzhen TargetRx Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New immune combo aims to fight lymphoma without chemo
Disease control Not yet recruitingOpen-Label, Phase 2 Chemotherapy-Free Study ofCD19 t-haNK and NAI in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Indolent Non-Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.
Phase 2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for liver cancer patients when immunotherapy stops working
Disease control Not yet recruitingThe goal of this clinical trial is to learn if lenvatinib or regorafenib can help treat people with advanced liver cancer (hepatocellular carcinoma, HCC) that cannot be removed with surgery after first treatment with immunotherapy-based drug combinations. It will also look at the…
Phase 2 • Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New trial tests whether education can shield teens from exploitation
Prevention Not yet recruitingAlthough the exact scope of commercial sexual exploitation of children (CSEC) remains unknown, its significant negative physical and emotional consequences for children has been well-documented. The U.S. government recognized the need for improved CSEC prevention over two decades…
Sponsor: University of New Hampshire • Aim: Prevention
Last updated Jun 27, 2026 12:01 UTC
-
Could engineered immune cells free diabetics from insulin shots?
Disease control Recruiting nowType 1 diabetes mellitus (T1DM) is a T cell-mediated autoimmune disease characterized by autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency and lifelong dependence on exogenous insulin. The disease results from loss of immune tolerance, with a…
Early phase 1 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Can a simple CT scan catch lung cancer early in indian smokers?
Diagnosis Not yet recruitingThe GLOBOCAN 2022 report for India, suggests lung cancer as the second most frequent cancer in males, with a case count at 58,970 forming 8.5% of the entire cancer burden for males in India. Upon including females, lung cancer still figures in the top five (ranked 4th) most frequ…
Sponsor: All India Institute of Medical Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Intensive PTSD therapy shows promise for rapid symptom relief in special operations troops
Disease control Recruiting nowOur long-term goal is to provide rapid and sustained reductions of trauma and cognitive-related symptoms among Special Operations personnel with PTSD or subthreshold PTSD. The primary objective of this project is to examine the effectiveness of massed PTSD treatment (i.e., CPT an…
Sponsor: Ohio State University • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Personalized coaching via smartphone could curb hypertension before it starts
Prevention OngoingThis community cluster-randomized controlled trial aims to evaluate the effectiveness of a hypertension risk model-based precision intervention among adults at high risk of developing hypertension in Shunyi District, Beijing, China. Four community clusters are included in the tri…
Sponsor: Peking University • Aim: Prevention
Last updated Sep 06, 2026 00:00 UTC